Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 14.17
(-0.14%)
USD 14.17
(-0.14%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 20.88 Million USD | -16.76% |
| 2022 | 25.08 Million USD | -5.65% |
| 2021 | 26.59 Million USD | -0.92% |
| 2020 | 26.83 Million USD | 184.11% |
| 2019 | 9.44 Million USD | 2295.51% |
| 2018 | 394.3 Thousand USD | 18.46% |
| 2017 | 332.86 Thousand USD | 20.43% |
| 2016 | 276.38 Thousand USD | 70.59% |
| 2015 | 162.01 Thousand USD | 12.21% |
| 2014 | 144.38 Thousand USD | -77.37% |
| 2013 | 638.07 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 14.79 Million USD | -14.41% |
| 2024 Q1 | 17.28 Million USD | -17.22% |
| 2023 Q1 | 24.83 Million USD | -1.01% |
| 2023 FY | 20.88 Million USD | -16.76% |
| 2023 Q4 | 20.88 Million USD | -8.63% |
| 2023 Q3 | 22.85 Million USD | -3.64% |
| 2023 Q2 | 23.71 Million USD | -4.5% |
| 2022 Q4 | 25.08 Million USD | -1.69% |
| 2022 Q3 | 25.52 Million USD | -0.84% |
| 2022 Q2 | 25.73 Million USD | -1.65% |
| 2022 Q1 | 26.17 Million USD | -1.58% |
| 2022 FY | 25.08 Million USD | -5.65% |
| 2021 FY | 26.59 Million USD | -0.92% |
| 2021 Q1 | 26.46 Million USD | -1.38% |
| 2021 Q3 | 25.9 Million USD | -0.69% |
| 2021 Q2 | 26.08 Million USD | -1.44% |
| 2021 Q4 | 26.59 Million USD | 2.65% |
| 2020 Q3 | 26.18 Million USD | 204.75% |
| 2020 Q1 | 9.03 Million USD | -4.34% |
| 2020 Q4 | 26.83 Million USD | 2.5% |
| 2020 FY | 26.83 Million USD | 184.11% |
| 2020 Q2 | 8.59 Million USD | -4.91% |
| 2019 FY | 9.44 Million USD | 2295.51% |
| 2019 Q4 | 9.44 Million USD | 13.44% |
| 2019 Q3 | 8.32 Million USD | 7.88% |
| 2019 Q2 | 7.71 Million USD | 2.02% |
| 2019 Q1 | 7.56 Million USD | 1818.81% |
| 2018 Q4 | 394.3 Thousand USD | 0.0% |
| 2018 Q3 | - USD | -100.0% |
| 2018 Q2 | 83.7 Thousand USD | -59.88% |
| 2018 Q1 | 208.64 Thousand USD | -37.39% |
| 2018 FY | 394.3 Thousand USD | 18.46% |
| 2017 FY | 332.86 Thousand USD | 20.43% |
| 2017 Q4 | 333.23 Thousand USD | 22385.56% |
| 2017 Q1 | 159.33 Thousand USD | -42.35% |
| 2017 Q3 | 1482.00 USD | -96.44% |
| 2017 Q2 | 41.6 Thousand USD | -73.89% |
| 2016 FY | 276.38 Thousand USD | 70.59% |
| 2016 Q2 | 23.33 Thousand USD | -74.9% |
| 2016 Q1 | 92.95 Thousand USD | -42.63% |
| 2016 Q4 | 276.38 Thousand USD | 5116.86% |
| 2016 Q3 | 5298.00 USD | -77.29% |
| 2015 Q2 | - USD | -100.0% |
| 2015 Q1 | 72.48 Thousand USD | -49.8% |
| 2015 Q4 | 162.01 Thousand USD | 0.0% |
| 2015 FY | 162.01 Thousand USD | 12.21% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q4 | 144.38 Thousand USD | 91.89% |
| 2014 Q2 | 638.5 Thousand USD | -0.05% |
| 2014 Q1 | 638.81 Thousand USD | 0.11% |
| 2014 FY | 144.38 Thousand USD | -77.37% |
| 2014 Q3 | 75.24 Thousand USD | -88.22% |
| 2013 FY | 638.07 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 638.07 Thousand USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | 42.839% |
| Dynavax Technologies Corporation | 256.91 Million USD | 91.871% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 49.709% |
| Perrigo Company plc | 4.07 Billion USD | 99.487% |
| Illumina, Inc. | 2.26 Billion USD | 99.077% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.94% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -1988.423% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.781% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.853% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 87.981% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.227% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 22.622% |
| Waters Corporation | 2.35 Billion USD | 99.113% |
| Biogen Inc. | 7.33 Billion USD | 99.715% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 45.191% |
| Evolus, Inc. | 126.54 Million USD | 83.497% |
| Adicet Bio, Inc. | 17.7 Million USD | -17.97% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 51.62% |
| bluebird bio, Inc. | 330.32 Million USD | 93.678% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 96.139% |
| FibroGen, Inc. | 170.45 Million USD | 87.748% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.236% |
| Homology Medicines, Inc. | 44.05 Million USD | 52.594% |
| Geron Corporation | 85.89 Million USD | 75.687% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.129% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 95.308% |
| Myriad Genetics, Inc. | 145 Million USD | 85.597% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -1557.479% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 81.894% |
| Zoetis Inc. | 6.8 Billion USD | 99.693% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -374.426% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.037% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 98.158% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 97.417% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 42.504% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 98.563% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 63.913% |
| Verastem, Inc. | 41.55 Million USD | 49.746% |
| Nektar Therapeutics | 230.4 Million USD | 90.936% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 88.794% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -579.383% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 98.505% |
| OPKO Health, Inc. | 326.56 Million USD | 93.605% |
| Exelixis, Inc. | 189.94 Million USD | 89.005% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 95.125% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -13730.617% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 84.911% |
| Imunon, Inc. | 1.13 Million USD | -1733.087% |
| Blueprint Medicines Corporation | 774.12 Million USD | 97.302% |
| Insmed Incorporated | 1.2 Billion USD | 98.265% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 98.607% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 63.353% |
| TG Therapeutics, Inc. | 110.79 Million USD | 81.151% |
| Incyte Corporation | 38.28 Million USD | 45.453% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 97.62% |